BriaCell Therapeutics Corp. shares swung between gains and losses on Monday after the company announced a genetic engineering milestone for its Bria-MEL+ melanoma vaccine candidate, which is designed to harness a patient’s immune system to combat the disease.
The stock initially surged about 25% in early trading before reversing course, leaving shares choppy for the session. Bria-MEL+ is a cell-based therapeutic cancer vaccine that uses a saliva test to select a premanufactured treatment cell line, enabling an off-the-shelf approach without individualized manufacturing for each patient.
The milestone advances the program toward clinical development and expands BriaCell’s therapeutic vaccine platform, which previously focused on metastatic breast cancer. The company now aims to extend the platform to include melanoma and prostate cancer.
BriaCell, based in Philadelphia and Vancouver, projects approximately 112,000 new melanoma cases and 8,510 deaths in the U.S. by 2026. The company’s CEO, William V. Williams, highlighted the potential of Bria-MEL+ to combine personalized immunotherapy with the accessibility of an off-the-shelf vaccine, potentially broadening access, shortening treatment timelines, and reducing costs while preserving patient-specific matching.
The company did not disclose further clinical timelines or regulatory steps following the milestone announcement.
